Background Vascular endothelial growth factor (VEGF) and VEGF receptor-2 (VEGFR-2)-mediated
signalling and angiogenesis can contribute to the pathogenesis and progression of …

Background Nivolumab plus ipilimumab produced objective responses in patients with
advanced renal-cell carcinoma in a pilot study. This phase 3 trial compared nivolumab plus …

Background Vascular endothelial growth factor (VEGF) inhibition is a valid therapeutic
approach in renal cell carcinoma. Therefore, an investigation of the combination treatment of the …

Background The combination of pembrolizumab and axitinib showed antitumor activity in a
phase 1b trial involving patients with previously untreated advanced renal-cell carcinoma. …

Background Lenvatinib in combination with pembrolizumab or everolimus has activity against
advanced renal cell carcinoma. The efficacy of these regimens as compared with that of …

Background Pembrolizumab is active in head and neck squamous cell carcinoma (HNSCC),
with programmed cell death ligand 1 (PD-L1) expression associated with improved …

… Négrier, Emilio Bajetta, Bohuslav Melichar Collection and assembly of data: Bohuslav
Melichar, Sergio Bracarda, … Bohuslav Melichar, Sophie Golding, Sangeeta Jethwa, Vesna …

Background Patients with renal-cell carcinoma who undergo nephrectomy have no options
for adjuvant therapy to reduce the risk of recurrence that have high levels of supporting …

Background The first interim analysis of the KEYNOTE-426 study showed superior efficacy
of pembrolizumab plus axitinib over sunitinib monotherapy in treatment-naive, advanced …

Background Pembrolizumab monotherapy showed durable antitumour activity and manageable
safety in patients with metastatic triple-negative breast cancer. We aimed to examine …